PAVmed (PAVM) Equity Income (2024 - 2025)
PAVmed (PAVM) recorded quarterly Equity Income of $2.5 million in Q4 2025, up 157.14% quarter-over-quarter from -$4.4 million in Q3 2025, and up 1903.2% on a YoY basis from $125000.0 in Q4 2024.
PAVmed (PAVM) Equity Income (2024 - 2025) Analysis & Trends
PAVmed's Equity Income history runs 2 years deep, the most recent figure standing at $2.5 million for Q4 2025.
- In Q4 2025, Equity Income rose 1903.2% year-over-year to $2.5 million; the TTM figure through Dec 2025 stood at $8.5 million (changed N/A YoY), while the FY2025 annual figure was $8.5 million, up 1494.55% from the prior year.
- Equity Income was $2.5 million for Q4 2025 at PAVmed, up from -$4.4 million in the prior quarter.
- In the past five years, Equity Income ranged from a high of $21.0 million in Q1 2025 to a low of -$10.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | - |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 4.68 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | - |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | PAVmed | 2.70 Mn | -10.47 Mn | -703,000.00 | 2.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.50 Mn |
| Sep 30, 2025 | -4.38 Mn |
| Jun 30, 2025 | -10.64 Mn |
| Mar 31, 2025 | 21.00 Mn |
| Dec 31, 2024 | 125,000.00 |